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Renoprotective benefits of RAS inhibition: From ACEI to ings have drawn attention to the importance of the RAS
angiotensin II antagonists. In landmark clinical trials, pharma- in the pathogenesis of CRD, and a large body of experi-
cological inhibition of the renin-angiotensin system (RAS) with mental evidence now attests to the central role of angio-angiotensin-converting enzyme inhibitors (ACEIs) attenuated
tensin II (Ang II) in several of the processes involvedthe decline in renal function associated with chronic renal dis-
in chronic renal injury. The development of orally activeease (CRD). Hemodynamic and nonhemodynamic effects of
angiotensin II (Ang II) attest to its central role in the pathogen- Ang II subtype 1 receptor antagonists (AT1RA) has pro-
esis of CRD. Angiotensin II subtype 1 receptor antagonists vided an alternate method of inhibiting the RAS, thereby
(AT1RA) differ from ACEI in their effects on the RAS and creating a novel potential therapy for CRD and affordingon bradykinin metabolism. Elevations in bradykinin levels as-
the opportunity to study in greater detail the role of thesociated with ACEI and stimulation of angiotensin subtype
2 receptors resulting from AT1RA may produce therapeutic RAS in CRD.
effects unique to each class of drug. Nevertheless, in animal
models of CRD, ACEI and AT1RA exert equivalent renopro-
tection, implying that their renoprotective effects result primar- ANGIOTENSIN II AS A CENTRAL EFFECTOR
ily from inhibition of Ang II-mediated stimulation of angioten- IN THE PATHOGENESIS OF CHRONIC
sin subtype 1 receptors. Clinical data comparing ACEI and RENAL INJURYAT1RA therapy in renal disease are limited to short-term stud-
ies, which indicate that AT1RAs have equivalent effects to The seminal studies of the renoprotective effect of
ACEI on the major determinants of CRD progression, namely ACEI were performed in rats subjected to 5/6 nephrec-
blood pressure and proteinuria. AT1RAs were well tolerated, tomy, a well-established model of progressive renal dis-with side-effect profiles similar to placebo. Taken together,
ease in which extensive renal mass ablation results inavailable evidence suggests that AT1RAs will share the reno-
a compensatory increase in single nephron glomerularprotective properties of ACEI in human CRD. Nevertheless,
the results of long-term clinical trials are required before filtration rate (SNGFR) and elevated glomerular capil-
AT1RA can be recommended as an alternative to ACEI in lary hydraulic pressure (Pgc), with subsequent develop-renoprotective therapy.
ment of proteinuria and focal glomerulosclerosis (GS).
Electron microscopy studies revealed that these changes
in glomerular hemodynamics were associated with evi-
Pharmacological inhibition of the renin-angiotensin dence of injury to visceral epithelial and glomerular en-
system (RAS) with angiotensin-converting enzyme in-
dothelial cells and mesangial expansion, as early as seven
hibitors (ACEIs) has been shown in landmark clinical
days after extensive renal mass ablation. Normalization
trials to dramatically attenuate the inexorable decline in
of glomerular hemodynamics by feeding rats a low-pro-
renal function associated with diabetic [1, 2] and nondia-
tein diet resulted in protection against these early struc-
betic [3–5] forms of chronic renal disease (CRD). There
tural lesions [6]. These observations led Brenner, Meyer,is now ample evidence to support the recommendation
and Hostetter to propose that the glomerular hemody-of ACEI therapy as the standard of care for strategies
namic adaptations consequent upon nephron loss ulti-aimed at preserving renal function in CRD. These find-
mately prove maladaptive and result in damage to re-
maining nephrons, thereby establishing a vicious cycle
of progressive nephron loss [7].Key words: angiotensin II receptor antagonists, blood pressure, pro-
teinuria, renin-angiotensin system, renoprotection. Control of glomerular hypertension, a feature of the
beneficial effect of the low-protein diet, was also achievedReceived for publication August 31, 1999
following treatment with the ACEI enalapril, which alsoand in revised form November 23, 1999
Accepted for publication November 24, 1999 largely prevented proteinuria and GS after 5/6 nephrec-
tomy [8]. Once again, in the micropuncture study, theÓ 2000 by the International Society of Nephrology
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hemodynamic effects of Ang II were found to be central tory component associated with chronic renal injury. Fi-
nally, Ang II stimulates adrenal production of aldosterone,to the pathogenesis of GS in this model. Whereas all rats
subjected to 5/6 nephrectomy had elevations in SNGFR which has been shown to contribute to renal injury in the
remnant kidney independent of the actions of Ang II [32].resulting from dilation of the afferent arteriole, the rise
in Pgc was prevented in enalapril-treated rats by concomi- The observation of suppressed levels of plasma renin
in rats after 5/6 nephrectomy [8] appears to argue againsttant efferent arteriolar dilation. Studies comparing ena-
lapril to combination antihypertensive therapy with re- a significant role for Ang II in chronic renal injury. How-
ever, identification of all of the components of the RASserpine, hydralazine, and hydrochlorothiazide revealed
that normalization of Pgc and the protection against GS within the kidney and the observation of higher Ang II
levels in kidney (particularly in proximal tubule fluid)are unique properties of ACEI, implying that Ang II is
a principal mediator of glomerular capillary hyperten- than in plasma indicate that Ang II is produced locally
in the kidney [33]. Dissociation between intrarenal andsion in the remnant kidney model [9]. This notion was
supported by previous studies that had found that infu- plasma Ang II levels has been shown in several animal
models, including two-kidney, one-clip Goldblatt hyper-sion of Ang II in normal rats results in a rise in Pgc [10–12]
and was confirmed by a subsequent study in which subcu- tension [34], Ang II-induced hypertension [35], hyper-
tensive ren-2 transgenic rats [36], and in rats after 5/6taneous infusion of Ang II for eight weeks caused sig-
nificant glomerular capillary hypertension, albuminuria, nephrectomy (abstract; Mackie et al, Am J Hypertens
12:24A, 1999). Thus, despite lower plasma renin levelsand GS [13].
Studies in rats with streptozotocin-induced diabetes in rats with remnant kidneys, the increased local renal
tissue RAS is thought to contribute to the observed pro-mellitus, a condition also associated with glomerular hyp-
erfiltration, glomerular capillary hypertension, and pro- gressive renal injury in this model.
The success of ACEIs as renoprotective agents in clini-gressive GS, produced similar results. Treatment with
enalapril normalized glomerular capillary pressure with- cal trials attests to a central role for Ang II in the patho-
genesis of human CRD progression. The first clinicalout significantly reducing filtration and prevented the
rise in proteinuria and GS seen in untreated controls study to show the renoprotective effects of ACEI was
conducted in patients with insulin-dependent diabetes[14]. In addition, ACEI have been shown to produce
significant renal protection in several other animal mod- mellitus (IDDM) and proteinuria of $500 mg/day. Treat-
ment with an ACEI significantly slowed the rate of de-els of CRD, including Fawn-hooded hypertensive rats
[15], hyperlipidemic Imai rats [16], radiation and bone cline in creatinine clearance and was associated with a
50% reduction in the risk of the combined end point ofmarrow transplant nephropathies [17], and GS associ-
ated with aging [18]. death, dialysis, or renal transplantation [1]. Subsequent
studies in patients with IDDM and microalbuminuriaAlthough these data together show that the glomeru-
lar hemodynamic effects of Ang II play a central role in found that ACEI treatment significantly reduces the inci-
dence of progression to overt proteinuria [37]. Amongthe pathogenesis of chronic renal injury, other studies
have revealed several nonhemodynamic effects of Ang II patients with non-insulin-dependent diabetes (NIDDM)
and microalbuminuria, several studies have shown thatthat may also be important (Fig. 1). In isolated, perfused
kidneys, infusion of Ang II results in a loss of glomerular ACEI treatment reduces or prevents an increase in albu-
minuria [38–43], and others have found beneficial effectssize permselectivity and proteinuria, an effect that has
been attributed to both hemodynamic effects of Ang II of ACEI on both albuminuria and rate of decline in
renal function [2, 44]. A benefit from ACEI treatmentresulting in elevations in Pgc, and a direct effect of Ang
II on glomerular permselectivity [19]. In vitro, Ang II in NIDDM patients with overt nephropathy has not been
clearly demonstrated to date. Although a nonrandom-has been shown to stimulate mesangial cell proliferation
and induce expression of transforming growth factor-b ized study found a decrease in incidence of end-stage
renal failure (ESRF) in NIDDM patients treated with(TGF-b), resulting in increased synthesis of extracellular
matrix (ECM) [20–22]. In vivo, transfection of rat kid- ACEI [45], small randomized studies have found no ben-
efit of ACEI therapy over other antihypertensivesneys with human genes for renin and angiotensinogen
resulted in glomerular ECM expansion within seven days [44, 46].
Angiotensin-converting enzyme inhibitor treatment[23]. Ang II also stimulates the production of plasmino-
gen activator inhibitor-1 (PAI-1) by endothelial cells and has also been found to be renoprotective in patients with
a variety of nondiabetic forms of CRD. The first studyvascular smooth muscle cells [24–26] and may therefore
further increase the accumulation of ECM through inhi- included large numbers of nondiabetic patients with re-
nal impairment and found a 53% reduction in the risk ofbition of ECM breakdown by matrix metalloproteinases,
which require conversion to an active form by plasmin reaching the combined end point of doubling of baseline
serum creatinine or the need for dialysis associated with[27]. By stimulating macrophage activation [28] and
phagocytosis [29–31], Ang II may enhance the inflamma- ACEI treatment. However, a significant difference in
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Fig. 1. Schema depicting the central role of angiotensin II, through hemodynamic and nonhemodynamic effects, in the pathogenesis of progressive
renal injury and fibrosis following nephron loss. Abbreviations are: ECM, extracellular matrix; mf , macrophage; PAI-1, plasminogen activator
inhibitor-1; Pgc, glomerular capillary hydraulic pressure; TGF-b, transforming growth factor-b.
blood pressure between patients receiving ACEI and tinued on ACEI actually showed an increase in GFR
placebo made it impossible to separate the beneficial after prolonged treatment [47]. Patients who received
effects of lowering blood pressure from any unique ef- ACEI from the start of the REIN study had a signifi-
fects of ACEI treatment [3]. By contrast, in the Ramipril cantly lower risk of reaching ESRF than those who
Efficacy in Nephropathy (REIN) study, patients with switched to ACEI after the initial phase of the study
nondiabetic CRD randomized to either ACEI or placebo (relative risk 5 1.86). Indeed, from 36 to 54 months of
achieved similar control of blood pressure. Among pa- follow-up, no further patients in the former group
tients with $3 g/day of proteinuria at baseline, the study reached ESRF [5]. Among patients with ,3 g/day of pro-
was stopped early because of a significantly lower rate teinuria, ACEI treatment also significantly reduced the
of decline in GFR in patients receiving the ACEI [4]. In incidence of ESRF (relative risk 5 2.72), particularly
the next phase of this study, patients who had previously among those with a GFR of ,45 mL/min at baseline [48].
received placebo were offered the opportunity to start
ACEI treatment, and those already on ACEI continued
PHARMACODYNAMICS OF ANGIOTENSIN-treatment. As anticipated, there was a significant reduc-
CONVERTING ENZYME INHIBITORtion in the rate of decline in GFR of patients switched
VERSUS ANGIOTENSIN SUBTYPE 1to ACEI. In addition, patients continuing on ACEI treat-
RECEPTOR ANTAGONISTSment showed a further reduction in the rate of GFR
Although both ACEI and AT1RA are effective indecline to levels similar to those associated with normal
aging. Interestingly, a small number of patients who con- inhibiting the RAS, they differ significantly in their ef-
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Fig. 2. Schema depicting the renin-angiotensin system and its interaction with the kinin system. Potential differences between the effects of ACEI
and AT1RA can readily be appreciated from this figure. Inhibition of angiotensin-converting enzyme (ACE) by ACEI results in enhanced kinin-
mediated effects, whereas blockade of AT1 receptors by AT1RA inhibits AT1 receptor-mediated effects and potentially enhances AT2 receptor-
mediated effects caused by elevated Ang II levels. Chymase and other serine proteases may convert Ang I to Ang II when ACE is inhibited by
ACEI. Abbreviations are: ACE, angiotensin-converting enzyme; ECM, extracellular matrix; mf , macrophage; PAI-1, plasminogen activator
inhibitor-1; Pg, prostaglandin; Pgc, glomerular capillary hydraulic pressure; RBF, renal blood flow; TGF-b, transforming growth factor-b.
fects on the components of the system (Fig. 2). Inhibition chymase and other serine proteases [51–53]. Indeed, dis-
ruption of the ACE gene results in animals with normalof ACE results in reduced conversion of Ang I to Ang II
and a compensatory rise in renin levels due to loss of serum levels of Ang II (abstract; Tian et al, J Invest Med
45:58A, 1997). ACE-independent production of Ang IInegative feedback inhibition of renin production by jux-
taglomerular apparatus (JGA) cells [49]. In contrast, has been demonstrated in several organs, although levels
of chymase were almost undetectable in the kidneyAT1RA produce elevations in both renin and Ang II
because normal feedback inhibition of JGA cells through [54–56]. The relevance of these findings to the efficacy
of ACEI in patients is unknown.stimulation of angiotensin II type 1 (AT1) receptors is
blocked [50]. These differences in the level of inhibition Second, it is now known that there are at least two
subtypes of AT receptor. Thus, blockade of subtype 1of the RAS may have important implications for the
therapeutic efficacy of AT1RA versus ACEI in at least (AT1) receptors in the presence of elevated Ang II levels
can be expected to result in stimulation of subtype 2two respects.
First, ACEIs are able to reduce only ACE-dependent (AT2) receptors. AT1 receptors mediate most of the
known effects of Ang II, including vasoconstriction, stim-Ang II production, whereas AT, RA block the effect of
Ang II from any source at the receptor level. In the ulation of aldosterone synthesis and release, and renal
tubule sodium and water reabsorption [57–59]. The rolepresence of ACE inhibition, studies have shown that
Ang II may be produced by other proteases, including of AT2 receptors, on the other hand, is not clearly de-
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fined. Although they do not appear to be involved in bradykinin; ACE inhibition therefore results in elevated
bradykinin levels [49, 74]. AT1RA, on the other hand,any of the main effects of Ang II, AT2 receptors are
important in fetal kidney development [60, 61]; modula- have no effect on bradykinin levels [50]. In several exper-
imental models, evidence suggests that elevated kininstion of pressure-natriuresis [54, 56]; Ang II-induced renal
production of nitric oxide [62]; and renal conversion of are responsible for at least some of the effects of ACEI.
Neointima formation following balloon injury to the ca-prostaglandin E2 to prostaglandin F2a [63]. In addition,
experimental evidence suggests that AT2 receptors may rotid artery is inhibited by ACEI, but the effect is lost
in animals cotreated with a kinin receptor antagonistcounterbalance some of the effects mediated by AT1
receptors. In cell culture, Ang II suppresses the prolifera- [75]. Similarly, in an animal model of cardiac failure, the
combination of bradykinin receptor blockade with ACEtion of fibroblasts selectively expressing AT2 receptors
[64]. Furthermore, vascular smooth muscle cells trans- inhibition significantly reduces the benefit of the latter
[70]. Furthermore, several of the effects of ACEI thatfected with an AT2 receptor expression vector attenuate
neointimal proliferation following balloon injury [65]. may contribute to renal protection have been attributed
to the associated rise in kinins, including: antihyperten-Pharmacogical inhibition of AT2 receptors and deletion
of the gene for the AT2 receptor have each been found sive effects in normal and hypertensive patients [76–79];
renal vasodilation resulting in increased renal blood flowto be associated with enhanced interstitial fibrosis in
models of unilateral ureteric obstruction [66, 67]. Disrup- [80–83]; dilation of the efferent arteriole and the associ-
ated fall in Pgc in normal rats subjected to intravasculartion of the AT2 receptor gene in mice results in a signifi-
cant increase in blood pressure and an enhanced pressor volume depletion [84] and salt-depleted rats with 1-kid-
ney, 1-clip hypertension [85]; antiproteinuric effects inresponse to exogenous Ang II [68]. In the isolated mi-
croperfused rabbit afferent arteriole, pretreatment with rats with passive Heymann nephritis [86] and puromycin
aminonucleoside (PAN) nephrosis [87]; tissue plasmino-an AT2 receptor antagonist completely abolishes the va-
sodilation associated with the administration of an gen activator release with resultant stimulation of ECM
AT1RA [69]. Taken together, these data suggest that degradation [88, 89]; and inhibition of monocyte/macro-
stimulation of AT2 receptors may produce antiprolifera- phage infiltration in unilateral ureteric obstruction [90].
tive, antifibrotic, and antihypertensive effects that might It is important to note, however, that these kinin-medi-
prove beneficial in the context of CRD. In a rat model ated effects of ACEI have been observed only in specific
of cardiac failure, the importance of AT2 receptor stimu- experimental models and are therefore not necessarily
lation has been demonstrated by the observation that relevant to the mechanisms involved in the progression
administration of an AT2 receptor antagonist blocks the of clinical CRD. In contrast, the observation that chronic
cardioprotective effect of AT1RA [70]. On the other administration of a kinin receptor blocker did not de-
hand, in one relatively short-term study, treatment with crease the renal protective effects of an ACEI in rats after
an AT2 receptor antagonist had no effect on the renal 5/6 nephrectomy [91, 92] or in streptozotocin-induced
protective effects of losartan in rats subjected to partial diabetes [93] suggests that kinin-mediated effects are not
renal ablation [71]. necessary for renal protection.
Differences between ACEI and AT1RA have also Elevated kinin levels may also be responsible for some
been observed with respect to their effects on aldoste- of the adverse effects associated with ACEI therapy.
rone levels. Among normotensive human subjects during The most common of these, dry cough, has been reported
low-sodium intake, both ACEI and AT1RA treatment in 5 to 20% of patients receiving ACEI and has been
lowered serum aldosterone levels, but this effect was proposed to be due, at least in part, to accumulation of
significantly greater for ACEI, despite equivalent hypo- kinins in the respiratory tract [94]. Angioneurotic edema,
tensive effects between the groups [72]. The same study a rare but potentially fatal complication of ACEI ther-
also found that ACEI treatment lowered plasma PAI-1 apy, may also result from raised tissue kinin levels [94].
antigen levels and activity, whereas no effect on PAI-1
was observed with AT1RA. However, both ACEI and
ANGIOTENSIN-CONVERTING ENZYMEAT1RA lowered PAI-1 expression in an experimental
INHIBITOR VERSUS ANGIOTENSINmodel of glomerulonephritis [73]. Since both aldosterone
SUBTYPE 1 RECEPTOR ANTAGONISTS IN RAT[32] and the fibrinolytic system may be involved in the
MODELS OF CHRONIC RENAL DISEASEpathogenesis of renal fibrosis, these differences may have
The development of orally active antagonists of thesignificant implications for the relative efficacy of these
AT1 receptor provided the means to test the implicationsagents as renoprotective drugs.
of the previously mentioned considerations for the effi-Angiotensin-converting enzyme inhibitor effects on
cacy of AT1RA as renal protective drugs in a variety ofhormonal systems other than the RAS may also contrib-
animal models. The large number of studies publishedute to some of their therapeutic effects. Thus, ACE, also
termed kininase II, is responsible for the breakdown of to date attests to the interest in this subject. Some studies
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have examined effects of AT1RA alone, but the most ACEI ramipril and AT1RA valsartan, both drugs were
useful have directly compared AT1RA with ACEI, the equally effective in preventing hypertension, proteinuria,
current “gold standard” in renal protective therapy. mesangial expansion, and glomerular basement mem-
brane thickening over 24 weeks [93]. A comparison of
5/6 Nephrectomy ACEI and AT1RA treatment in a model of type 2 diabe-
The first study in this well-established model of sec- tes [111] and in a model in which the progression of
ondary focal and segmental glomerulosclerosis (GS) by diabetic nephropathy was accelerated by uninephrec-
Lafayette et al compared the effects of the ACEI enala- tomy [112] again produced similar results. ACEI and
pril, the AT1RA losartan, and combination antihyperten- AT1RA have also been shown to be equally effective in
sive therapy with hydralazine, reserpine, and hydrochlo- preventing glomerular up-regulation of monocyte che-
rothiazide commencing two weeks after surgery [95]. moattractant protein-1 (MCP-1) and macrophage infil-
After 19 weeks of therapy and equivalent blood pressure tration, as well as delaying the increase in expression of
control in all treatment groups, animals in both the ACEI TGF-b1 in diabetic rats [113].
and AT1RA groups had significantly less proteinuria
than untreated controls and combination antihyperten- Hypertensive renal injury
sive-treated rats. Similarly, histology of the remnant kid- Angiotensin subtype 1 receptor antagonists have been
ney revealed significant and equal protection in the compared with ACEI in several models of hypertensive
ACEI and AT1RA groups. Micropuncture studies dem- renal disease. In Fawn-hooded hypertensive rats (a
onstrated a similar reduction in glomerular pressure with model of genetically determined hypertension and pro-
losartan and enalapril, indicating that with both treat- gressive renal injury) subjected to uninephrectomy to
ments, renal protection was achieved through normaliza- accelerate the development of GS, enalapril and the
tion of Pgc. Subsequent studies in the same model have AT1RA irbesartan lowered blood pressure and Pgc to a
confirmed these findings using different ACEI and similar degree and afforded equivalent renal protection
AT1RA [96–102]. In addition, Kakinuma et al found [114]. Comparisons in other models, including 2-kidney,
similar degrees of protection from arterial wall thick- 1-clip Goldblatt hypertension [115], spontaneously hy-
ening with ACEI and AT1RA [103]. Recently, studies pertensive rats (SHR) subjected to uninephrectomy
have focused on the effect of treatment on molecular [116], and stroke-prone SHR [117–119], have reported
mediators of renal injury. Several studies have observed similar reductions in blood pressure, proteinuria, and
equivalent effects of ACEI and AT1RA in preventing renal injury with ACEI versus AT1RA treatment. Can-renal up-regulation of the profibrotic cytokine TGF-b
desartan and enalapril were equally effective in reducing
[104, 105]. Other investigators have found ACEI and
proteinuria, renal mRNA levels for TGF-b1 and ECMAT1RA to be equally effective in inhibiting expression components, and histologic injury in deoxycorticoster-of a variety of proinflammatory cytokines (abstract; Taal
one-salt hypertensive rats, although neither treatmentet al, J Am Soc Nephrol 10:670A, 1999) and macrophage
reduced systemic blood pressure [120]. In other experi-recruitment [106] in the remnant kidney. One group
ments, candesartan prevented the increase in glomerularhas also reported that losartan was more effective than
expression of TGF-b1 and fibronectin seen in untreatedcaptopril in preventing increased renal production of
stroke prone SHR [121] and ameliorated the proteinuriaendothelin-1, but there was no difference in effect on
and arterial lesions associated with l-NAME–inducedblood pressure or proteinuria [107]. A single study, in
hypertension [122]. In salt-loaded, stroke-prone SHR, awhich treatment was delayed until well after substantial
model of malignant hypertension, losartan attenuated therenal injury had occurred, reported significant protection
rise in blood pressure, reduced proteinuria, and delayedwith the AT1RA, candesartan, but only a nonsignificant
the appearance of malignant hypertensive nephroscl-decrease in GS with enalapril [108]. This finding, how-
erosis [123].ever, could not be confirmed in another long-term study
of similar design in which enalapril and candesartan
Other modelsproved equally renoprotective [109].
Other models in which the effects of AT1RA have
Diabetic nephropathy been evaluated include late renal allograft injury [124–
127], passive Heymann nephritis [128], mesangioproli-In a study of similar design to that which first demon-
ferative nephritis [129, 130], Thy 1.1 glomerulonephritisstrated long-term renal protection by enalapril in dia-
[73], spontaneous age-related GS in MWF/Ztm rats [131],betic rats, treatment with losartan prevented the early
spontaneous GS in hyperlipidemic Imai rats [132], andrise in GFR observed in untreated rats and during one
cyclosporine nephropathy [133]. In each case, AT1RAyear of follow-up effectively prevented hypertension,
treatment has resulted in renal protection equivalent toproteinuria, and GS to an extent similar to that reported
for enalapril [110]. In a direct comparison between the that of ACEI.
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Combination therapy ies [137], and similar observations have been reported
in nondiabetic renal disease. Data from the MRFIT studySince ACEI and AT1RA inhibit the RAS at different
identified elevated blood pressure as a strong, indepen-levels, it is of interest to ascertain whether their effects
dent risk factor for end-stage renal disease (ESRD) inare additive or even synergistic. This notion is supported
332,544 prospectively evaluated men [138], and re-analy-by the observation that in (mRen-2)27 transgenic rats,
sis of the MDRD study, which included patients withtreatment with a combination of enalapril and losartan
CRD of diverse etiologies, showed that those with lowestresulted in higher plasma renin concentrations than ei-
achieved levels of blood pressure had lowest rates ofther drug alone [134]. In addition, in rats subjected to
decline in GFR [139]. Experimental evidence also sup-5/6 nephrectomy, combination treatment with valsartan
ports the concept that blood pressure contributes directlyand benazepril resulted in greater renal protection than
to glomerular injury. Using repeated radiotelemetriclow doses of either drug alone (abstract; Cohen et al,
measurements of blood pressure, Bidani et al found aJ Am Soc Nephrol 7:1852, 1996). In rats with passive
strong correlation (r 5 0.88) between mean systolicHeymann nephritis, combination therapy with lisinopril
blood pressure and GS [140]. Furthermore, when theand the AT1RA L-158,809 was associated with a greater
level of blood pressure was varied by using two differentreduction in proteinuria and a trend toward less GS than
doses of enalapril after 5/6 nephrectomy, Ots et al ob-either treatment alone (abstract; Zoja et al, J Am Soc
served greater levels of proteinuria and a trend towardNephrol 6:860, 1995). On the other hand, combination
more severe GS in rats with moderately elevated bloodtreatment with losartan and enalapril was no more reno-
pressures than in those with normalized blood pressureprotective than either drug alone in 5/6 nephrectomized
[99]. Micropuncture studies in 5/6 nephrectomized ratsrats when doses were adjusted so that monotherapy nor-
have suggested that it is Pgc, rather that the systemicmalized blood pressure and combination therapy low-
blood pressure per se, that is the critical determinant ofered blood pressure to the same extent [99]. Similarly,
renal injury [9, 141]. However, ACEI [9] and AT1RAa combination of captopril and losartan treatment in
[95, 101] have each been shown to reduce both systemicdiabetic SHR rats subjected to uninephrectomy did not
and glomerular capillary pressures, and it thereforeresult in greater reductions in blood pressure or better
seems reasonable to regard systemic blood pressure asrenal protection that either treatment alone [112]. In the
a surrogate for Pgc in this setting. This is not a universalThy 1.1 glomerulonephritis model, combination therapy
finding with antihypertensive therapies, however, sincewith enalapril and losartan had no benefit over mono-
not all drugs that lower systemic pressures also lowertherapy [73]. These early data indicate that a combina-
glomerular capillary pressure as effectively as RAS in-tion of ACEI and AT1RA treatment may be beneficial
hibitors [9, 95].when adequate blockade of the RAS is not achieved with
In healthy volunteers, AT1RAs have little or no effectmonotherapy, but the question of whether combination
on systemic blood pressure, GFR or filtration fractiontherapy results in greater renal protection than effective
(FF), even though plasma renin activity and plasma Angmonotherapy requires further investigation.
II levels become elevated and aldosterone levels de-
crease [142, 143]. In patients with mild to moderate es-
ANGIOTENSIN SUBTYPE 1 RECEPTOR sential hypertension, AT1RAs are effective in lowering
ANTAGONISTS IN CLINICAL STUDIES systemic blood pressure [144–151], and the antihyperten-
sive effects of AT1RA have been shown to be equivalentTwo large randomized, multicenter control trials of
the effects of AT1RA in type 2 diabetic nephropathy are to those of atenolol [152, 153], hydrochlorothiazide [154],
calcium antagonists [151, 155], and ACEI [156–160]. Itcurrently in progress (RENAAL, involving losartan, and
IDNT, involving irbesartan). Therefore, clinical data are should be noted that for both ACEI and AT1RA, the
maximum antihypertensive effect may be observed aftercurrently limited to short-term studies with small num-
bers of patients that have assessed the effects of AT1RA only six weeks of therapy [157]. An assessment of the
full response to treatment should therefore be delayedon parameters that may predict long-term renal protec-
tion. until after six weeks.
Since the unique renal protective effects of ACEI are
Systemic and renal hemodynamic effects associated with their favorable effects on renal hemody-
namics, several studies have sought to evaluate the ef-The observation of dramatic reductions in the rates of
decline of GFR following initiation of antihypertensive fects of AT1RA on renal hemodynamics. In 17 patients
with essential hypertension, a single dose of candesartantherapy in insulin-dependent diabetic patients with dia-
betic nephropathy indicated that hypertension, an almost cilexetil lowered mean arterial pressure (MAP) and sig-
nificantly reduced renal vascular resistance (RVR), re-universal consequence of impaired renal function, con-
tributes to the progression of CRD [135, 136]. These sulting in an increase in effective renal plasma flow
(ERPF). GFR also increased, but the FF was not signifi-findings have subsequently been confirmed in many stud-
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cantly changed [161]. The effects of chronic therapy were in the incidence of the primary end-point (10.5% in each)
or in the extent to which cardiac failure was improved,evaluated in another study in which 20 patients with
essential hypertension and normal serum creatinine con- indicating that losartan and captopril have equivalent
systemic and renal hemodynamic effects in this patientcentrations were randomized to receive either irbesartan
or enalapril for 12 weeks. The treatments were equally population [168]. Small, stable increases in serum creati-
nine have also been reported in studies of AT1RA ineffective in lowering mean ambulatory blood pressure,
and both resulted in decreases in RVR and increases in patients with hypertension and renal impairment [169]
and in renal transplant recipients [170]. Similar increasesERPF with no average change in GFR. Although there
were no statistically significant differences between the in serum creatinine have previously been observed in
patients with renal impairment after initiation of ACEIeffects of irbesartan versus enalapril, the authors re-
ported some differences in the time course of the effects, treatment [3]. Whereas a progressive increase in serum
creatinine should be regarded as an indication for discon-with enalapril producing earlier but less sustained effects
than irbesartan [162]. Other studies have reported no tinuing ACEI or AT1RA treatment, small, stable in-
creases should be expected in some patients with pre-change in renal hemodynamic parameters in patients with
essential hypertension treated with AT1RA [163, 164]. existing renal impairment. One study has shown that
patients who experienced an initial decline in GFR afterOf more direct relevance to the potential renal protec-
tive effects of AT1RA are studies of patients with hyper- starting antihypertensive treatment subsequently had a
lower rate of decline in GFR than patients who did nottension and renal disease as evidenced by reduced GFR
or proteinuria. In the first published study of this kind, have an initial decline in GFR [171]. Thus, a small, stable
increase in serum creatinine after the initiation of ACEI11 patients with hypertension and proteinuric CRD with
normal or mildly impaired renal function (creatinine or AT1RA is probably hemodynamic in origin, reflecting
a fall in intraglomerular pressure, and may thereforeclearance $60 mL/min) were treated first with two differ-
ent doses of the AT1RA, losartan, and then with the predict long-term renal protection. It should not be re-
garded as an indication for stopping treatment.ACEI, enalapril at two different doses. Both treatments
produced a reduction in MAP, an increase in ERPF, a Available clinical data therefore indicate that in pa-
tients with essential hypertension or with hypertensiondecrease in FF, and no change in GFR. There were no
significant differences between the treatments and also associated with renal impairment, AT1RA therapy pro-
duces systemic and renal vasodilation equivalent to ACEIno differences between the different doses [165]. In 84
patients with more severe renal disease (creatinine clear- therapy. Since the renal protective effects of ACEI are
attributable to a large extent to their renal hemodynamicance #60 mL/min), losartan was effective in lowering
systemic blood pressure and produced no significant effects, it seems reasonable to anticipate that AT1RA
will also share the long-term renal protection associatedchange in mean creatinine clearance over 12 weeks of
therapy. In 11 patients in whom GFR and ERPF were with ACEI.
measured, mean GFR and ERPF were unchanged after
Proteinuriaeight weeks of losartan therapy [166]. In 17 patients with
hypertension and GFRs ranging from 161 to 11 mL/min Abnormal excretion of protein in the urine has long
been recognized as a marker of glomerular injury, and(mean 60 mL/min), a single dose of candesartan cilexetil
produced a reduction in MAP, increase in ERPF, fall in microalbuminuria predicts the development of overt ne-
phropathy in patients with diabetes mellitus [172, 173].FF, and no change in GFR. These changes were sus-
tained after five days of therapy. Interestingly, there was Observations from the MDRD Study and the REIN
Trial, however, suggest that proteinuria may also be aa correlation between the magnitude of the initial change
in ERPF or FF and the pretreatment GFR, which was significant independent determinant of CRD progres-
sion. Both studies reported a strong association of greaterno longer present after five days, indicating that although
patients with preserved renal function showed a greater baseline proteinuria with more rapid decline in GFR.
The MDRD Study found that a reduction of proteinuriaresponse initially, patients with renal impairment achieved
an equivalent response by day 5 [167]. independent of the reduction in blood pressure was asso-
ciated with a further decrease in the rate of decline inThe renal hemodynamic effects of losartan have also
been evaluated in older patients with cardiac failure. In GFR and that the degree of renoprotection achieved by
lowering blood pressure below usual target levels wasthe ELITE trial, 722 patients .65 years, with New York
Heart Association class II–IV cardiac failure and serum dependent on the level of proteinuria [139]. In the REIN
Trial, treatment with ramipril reduced proteinuria tocreatinines ,2.5 mg/dL, were randomized to treatment
with either losartan or captopril and followed for eight an extent that showed an inverse correlation with the
subsequent rate of decline in GFR [4]. In addition, pro-weeks. The primary end-point for the study was the
incidence of a persistent rise in serum creatinine of $0.3 teinuria has been identified as an important predictor
of cardiovascular mortality in both nondiabetic subjectsmg/dL. There was no difference between the treatments
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[174–176] and in patients with type 2 diabetes [177]. 7.5 mm Hg, respectively), this difference is unlikely to
account for the observed differences in albuminuriaFinally, there is growing evidence that abnormal amounts
of filtered protein may contribute directly to the patho- [187]. A crossover study in 15 patients with nondiabetic
CRD and hypertension reported a reduction in protein-genesis of progressive renal injury. In vitro studies have
shown that exposure of mesangial cells to plasma lipo- uria after four weeks of losartan treatment, but no effect
with amlodipine despite equivalent control of bloodproteins results in proliferation, synthesis, and elabora-
tion of ECM proteins, and expression of proinflammatory pressure [188].
To date, a single randomized study has evaluated thecytokines, all of which may contribute to the pathogenesis
of GS [178, 179]. More recently, a variety of proteins antiproteinuric effects of AT1RA among patients with
primary renal disease and proteinuria. Twenty patientshas been shown to be directly toxic to tubular epithelial
cells and to induce production of proinflammatory cyto- with biopsy-proven IgA nephropathy proteinuria and se-
rum creatinines ,2.5 mg/dL were randomized to receivekines and ECM proteins [180–183]. The renal protection
afforded by ACEI therapy is closely associated with the enalapril or irbesartan. After four weeks of therapy, both
treatments resulted in significant and equivalent reduc-antiproteinuric effects of these drugs, and evaluation of
the effects of AT1RA on urinary protein excretion may tions in proteinuria (61 and 55% for enalapril and irbe-
sartan, respectively). A small increase in ERPF wastherefore give some indication of their potential as renal
protective agents. noted in both groups, but no change in GFR or FF [189].
Two studies have compared the antiproteinuric effects
Combination therapyof AT1RA and other antihypertensives in patients with
essential hypertension in the absence of overt nephropa- Data on the use of combination ACEI and AT1RA
therapy in humans is extremely limited. One study inthy. When compared with the ACEI enalapril, losartan
produced an equivalent control of blood pressure after 12 sodium-depleted normal subjects observed a greater
reduction in blood pressure and greater increases in12 weeks of therapy in 93 patients and significant and
equivalent reductions in the urinary albumin-to-creati- plasma active renin after the addition of losartan to ena-
lapril treatment than after doubling the dose of enalapril,nine ratio [184]. In contrast, when losartan was compared
with the calcium antagonist felodipine in 29 older Chi- suggesting that the combination resulted in more effec-
tive inhibition of the RAS [190]. Similarly, in seven dia-nese patients with hypertension, the AT1RA produced
a mean reduction of 27% in urinary albumin excretion betic patients receiving ACEI, the addition of an AT1RA
was associated with a significant rise in plasma reninafter 12 weeks of therapy, whereas albuminuria was un-
changed in the group receiving the calcium antagonist levels (abstract; Falkenhain et al, J Am Soc Nephrol
8:110A, 1997). A pilot study that included 11 patientsdespite equivalent control of blood pressure [185].
In patients with hypertension and CRD, the equivalent with CRD of various etiologies reported a further 30%
reduction in proteinuria, a 6 mm Hg fall in MAP, andrenal hemodynamic effects of enalapril and losartan de-
scribed earlier in this article were accompanied by a no change in creatinine clearance two weeks after the
addition of an AT1RA to their prior ACEI therapy [191].reduction of approximately 50% in proteinuria in both
groups [165]. Similarly, 12 weeks of losartan therapy In eight patients with IgA nephropathy who were treated
in a serial manner with ACEI alone, combination ACEIresulted in a 23% reduction in proteinuria in patients
with moderate to severe renal impairment [166], and and losartan, losartan alone, and combination again,
ACEI or AT1RA treatment produced equivalent reduc-valsartan treatment resulted in a 26% reduction in pro-
teinuria, which was associated with a 51% decrease in tions in proteinuria, and the combination therapy re-
sulted in greater antiproteinuric effects than either treat-fractional clearances of high molecular weight dextrans,
indicating a significant improvement in glomerular per- ment alone without significant additional hypotensive
effects [192]. There are currently no data available onmselectivity [186]. In renal transplant recipients, losartan
lowered blood pressure and reduced proteinuria, while the long-term effects of combination therapy in human
nephropathies.serum creatinine concentration was increased only mini-
mally [170]. A comparison with the calcium antagonist
Comparison of different angiotensin subtype 1amlodipine confirmed the unique antiproteinuric effects
receptor antagonistsof inhibitors of the RAS. Among 48 patients with creati-
nine clearance in the range of 30 to 60 mL/min, 12 weeks Pharmacological studies have revealed differences
among the clinically available AT1RA (losartan, valsar-of losartan were associated with a 19% decrease in mean
albuminuria, whereas amlodipine resulted in a 32% in- tan, candesartan, irbesartan, eprosartan, and telemisar-
tan) with respect to bioavailability, plasma half-life, andcrease in mean albuminuria. Although patients receiving
losartan achieved a significantly greater reduction in sys- relative affinity for the AT1 receptor [193]. Direct com-
parisons over eight weeks suggest that the longer actingtolic and diastolic blood pressures (227.7 6 15.2 vs.
216.3 6 12.1 mm Hg and 218.8 6 7.2 vs. 212.4 6 AT1RAs, candesartan and irbesartan, may be more effec-
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tive at lowering trough-level blood pressure than the these models predicted their success as renal protective
agents in human renal disease makes it reasonable toshorter acting losartan [194–196]. Long-term prospective
trials will be required, however, to evaluate whether anticipate that AT1RA will also prove effective in slow-
ing the progression of human chronic nephropathies.any of these differences result in differences in clinical
outcomes. Although clinical data directly evaluating the long-term
renal protection by AT1RA are still awaited, early studiesUnique among the AT1RA is the uricosuric effect of
losartan, which has been observed in normal subjects indicate that they exert equivalent effects to ACEI on the
major determinants of renal disease progression, namely[142], hypertensive patients [160, 197, 198], and hyperuri-
cemic cardiac transplant recipients [199], and which re- blood pressure and proteinuria. Based on available evi-
dence, ACEI should still be regarded as the first line ofsults in sustained decreases in serum uric acid levels.
Increased urinary excretion of uric acid has been attrib- therapy in renal protection, but in those patients denied
the benefits of ACEI because of side effects, AT1RAuted to competitive inhibition of uric acid reabsorption
in the renal proximal tubule by the parent compound will likely provide a valuable alternative means of inhib-
iting the RAS.losartan (but not its active metabolite) [200, 201]. Epide-
miological evidence of an association between hyperuri-
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